International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee.
H pylori
ITP
immune thrombocytopenia
international survey
platelets
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
18
08
2020
revised:
29
09
2020
accepted:
08
10
2020
pubmed:
19
10
2020
medline:
15
5
2021
entrez:
18
10
2020
Statut:
ppublish
Résumé
Essentials When to test and treat H pylori among patients with ITP is controversial. We report the results of an international survey administered to physicians with experience treating ITP across 39 countries. The decision to test for H pylori was influenced by country, country of origin, and concomitant gastrointestinal symptoms. Testing and treating for H pylori among patients with ITP varied across geographic regions. ABSTRACT: Background Investigations for patients suspected of immune thrombocytopenia (ITP) lack standardization. A controversial issue is whether such patients should be tested for Helicobacter pylori, a known cause of secondary ITP. Objectives This Scientific and Standardization Committee Communication reports the results of an international survey to describe patterns of practice with respect to screening and treatment of H pylori among patients with ITP. Patients/Methods A 17-item scenario-based questionnaire was delivered to hematologists in countries across the world. The questionnaire was pilot tested before use. We used snowball sampling and a contact list of physicians from the Platelet Disorders Support Association to identify survey respondents. Data were analyzed descriptively. Results A total of 186 respondents from 39 countries completed the survey. Response rate from the snowball sample was 53.6%. Twenty-nine percent (n = 55) of respondents always tested ITP patients for H pylori, and 53% (n = 98) sometimes tested. Of the 37 respondents from Asia and the Middle East, 51.4% (n = 19) always tested for H pylori for the stated reasons of high local prevalence and perceived benefit of treatment on platelet count levels. Respondents were more likely to test patients who were from Asia (145/177, 80%) and who had concomitant gastrointestinal symptoms (133/183, 72%). For eradication therapy, 71 of 118 (60.2%) respondents used the combination of a proton pump inhibitor, clarithromycin, and amoxicillin for 14 days. Conclusions This international survey showed that testing for H pylori was most common in Asia and in patients from Asia. Testing and treating practices varied across geographic regions.
Identifiants
pubmed: 33070448
doi: 10.1111/jth.15136
pii: S1538-7836(22)00444-5
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-296Informations de copyright
© 2020 International Society on Thrombosis and Haemostasis.
Références
Eshraghian A. Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean region: a systematic review of prevalence and risk factors. World J Gastroenterol. 2014;20(46):17618-17625.
Hooi JKY, Lai WY, Ng WK, et al. Systematic review and meta-analysis. Gastroenterology. 2017;153:420-429.
Novis BH, Gabay G, Naftali T. Helicobacter pylori: the Middle East scenario. Yale J Biol Med. 1998;71(2):135-141.
Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449-490.
Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231-1240.
Inaba T, Mizuno M, Take S, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005;35:214-219.
Frydman GH, Davis N, Beck PL, Fox JG. Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography. Helicobacter. 2015;20(4):239-251.
Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
Castro Ozelo M, Pereira Colella M, Vinícius de Paula E, et al. Guideline on immune thrombocytopenia in adults: Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Hemoterapia e Terapia Celular. Project guidelines: Associacão Médica Brasileira. Hematol Transfus Cell Ther. 2018;40(1):50-74.
Kashiwagi H, Kuwana M, Hato T, et al. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 revision. Int J Hematol. 2020;111(3):329-351.
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
Harris PA, Ph D, Taylor R, et al. Research Electronic Data Capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics. J Biomed Inform. 2009;42(2):377-381.
Johnston LG, Hakim AJ, Dittrich S, Burnett J, Kim E, White RG. HHS public access. 2019;20(8):1754-1776.
Jung M. Probability sampling method for a hidden population using respondent-driven sampling: simulation for cancer survivors. Asian Pac J Cancer Prev. 2015;16(11):4677-4683.
Platelet Disorder Support Association [Internet]. https://www.pdsa.org
Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola PGG. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352(9131):878.
Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol. 2014;20(3):714-723.
Michel M, Khellaf M, Desforges L, et al. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection. Arch Intern Med. 2002;162:1033-1036.
Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004;124(1):91-96.
Pellicano R, Touscoz GA, Smedile A, et al. Prevalence of non-organ-specific autoantibodies in patients suffering from duodenal ulcer with and without Helicobacter pylori infection. Dig Dis Sci. 2004;49(3):395-398.
Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009;7(2):322-329.
Osaki T, Konno M, Yonezawa H, et al. Analysis of intra-familial transmission of Helicobacter pylori in Japanese families. J Med Microbiol. 2015;64:67-73.
Arnold DM, Bernotas A, Nazi I, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94(6):850-856.